Contact Us

Contact Person : Michael Liu

Phone Number : +86-13631598551

Free call

Ischemic Stroke Treat Multi Frequency Photobiomodulation Helmet

Minimum Order Quantity : 1 Price : negotiable
Packaging Details : 1pcs/box Delivery Time : 3-7work days
Payment Terms : L/C, D/A, D/P, T/T, Western Union, MoneyGram,PayPal Supply Ability : 1000
Place of Origin: China Brand Name: SSCH
Certification: CE Model Number: GY-PDT1

Detail Information

Product Name:: Blood Photobiomodulation Therapy Machine Function 1: Treat Ischemic Stroke, Traumatic Brain Injury,
LED Quantity:: 256pcs Power 1:: 60 MW Per LED, Total 15 W
Certificate:: CE Color:: White
Function 2:: Alzheimer's Disease, Parkinson's Diseas Wavelength:: 810 Nm
Power 2:: 24 MW/cm2 OEM:: Supported
High Light:

Multi Frequency Photobiomodulation Helmet

,

Ischemic Stroke Treat Photobiomodulation Helmet

,

CE Photobiomodulation Machine

Product Description

Brain Photobiomodulation Helmet Advanced - Multi Frequency

 

brainhelmet2uses.jpg

brainlighttablet.jpg helmettablet.jpg

The Advanced Helmet Multi Frequency 0 - 20,000 Hz with Touchscreen Controller (Basic Helmet is 40 Hz only and manual controller)

Our helmet device works with 810 nm infrared, it can extend through the skull into the brain, offers an unique array of neurological benefits.

Compared with other therapy method, like drugs, light therapy is the most safe and no side effects way for treatment.
Light therapy was known in medical field for a long time, especially for the red light and infrared.


All our clients feel good spirit and comfortable after using.


Our device works with 810nm infrared, it can extend through the skull into the brain, offers an unique array of neurological benefits. It usually be used for treating metastatic lesions in deep tissues as well as in bones. And also be used for cancer cell imaging, as well as circulating tumor cell detection and destruction.

 

1.The 810 nm wavelength has the ability to extend through the skull to the brain, promoting recovery from traumatic brain injury and reducing long-term nerve damage.
2.810nm wavelength can help patients with severe depression and anxiety
3. NIR light is absorbed by cytochrome C oxidase in mitochondria.
4. Increased blood flow, energy, neuroprotection and less inflammation.
5. treat traumatic (stroke, TBI), neurodegenerative and psychiatric diseases.

 

1,Introduction

 

Photobiomodulation (PBM) describes the use of red or near-infrared light to stimulate, heal, regenerate, and protect tissue that has either been injured, is degenerating, or else is at risk of dying. One of the organ systems of the human body that is most necessary to life, and whose optimum functioning is most worried about by humankind in general, is the brain.

 

The brain suffers from many different disorders that can be classified into three broad groupings: traumatic events (stroke, traumatic brain injury, and global ischemia), degenerative diseases (dementia, Alzheimer’s and Parkinson’s), and psychiatric disorders (depression, anxiety, post traumatic stress disorder). There is some evidence that all these seemingly diverse conditions can be beneficially affected by applying light to the head. There is even the possibility that PBM could be used for cognitive enhancement in normal healthy people.

 

In this transcranial PBM (tPBM) application, near-infrared (NIR) light is often applied to the forehead because of the better penetration (no hair, longer wavelength).

 

PBM therapy was developed more than 50 years ago; however, there is still no common agreement on the parameters and protocols for its clinical application. Some research teams have recommended the use of a power density of less than 100 mW/cm2 and an energy density of 4 to 10 J/cm2 [11]. Others groups recommend as much as 50 J/cm2 at the tissue surface [11]. Parameters like wavelength, energy, fluency, power, irradiance, pulse mode, treatment duration, and repetition rate can be applied in a wide range. Our present preliminary results showed a clear response of cerebral rSO2 in relation to the LED stimulation. However, it has to be mentioned that the temperature increased significantly, and these effects have to be taken into account in further studies in detail. There is also the fact that ineffective studies in cells with high mitochondrial activity appear to be due more often to over-dosing than to under-dosing [11]. Therefore, clinical studies concerning the optimal stimulation doses are necessary.

2,Clinical application

Medically speaking a wide range of neurological and psychological disorders affects various cerebral structures. Recent clinical brain PBM therapy studies have been focused on conditions such as AD, PD, TBI and ischemic stroke as well as MDD. However there is also a growing interest for application of this non-invasive modality in perfectly healthy individuals to improve their cognitive abilities (cognitive enhancement)

1.1. Alzheimer’s disease

Despite the existence of several animal studies, there have only been a few studies on the efficacy of PBM therapy in AD and dementia patients. Regarding these human studies, significant improvements in sleep quality, mood states, EEG patterns as well as improved cognitive function including memory and attention, have been obtained as a consequence of NIR PBM therapy [71,195]. Besides, red laser delivered via an arterial catheter leading into the brain gave improvement of CBF in AD patient, and also resulted in a remarkable reduction of dementia scores [196].

 

2.2. Parkinson’s disease

To date, the majority of the clinical investigations revealed positive impacts of transcranial PBM therapy in conditions such as TBI, stroke and depression, in which the target area was in the cortical regions of the brain. On the other hand, PD pathogenesis is linked to abnormalities in the SNc, a midbrain structure that is located at a depth 80–100 mm from the coronal suture, below the dura. Studies have suggested that light in the NIR region may not penetrate the human brain deeper than 20 mm from the cortical surface [68]. This is considered to be a clear limitation in the application of transcranial PBM therapy in human PD. However, in the only (non-controlled, non-randomized) study in PD patients, improved motor and cognitive functions has been reported following 2 weeks of transcranial PBM therapy [197].

3.3 Traumatic brain injury

So far, although the majority of animal studies have been conducted on acute TBI models, by contrast the majority of clinical studies have been conducted on chronic TBI patients. It is quite common for humans who recover from a moderate or severe head injury to suffer from a wide variety of long-lasting symptoms including cognitive impairment (eg, poor memory, impaired executive function, and difficulties concentrating), headaches, disturbed sleep, and depression. In the early open studies in TBI, transcranial LED therapy (633/870 nm) improved self-awareness, self-regulation in social functioning and sleep quality [30,33]. The higher fluence of NIR laser resulted in greater clinical efficacy such as diminished signs of headache and improved sleep quality as well as improved cognitive and mood states in TBI patients [61]. In addition, improving the alertness and awareness in TBI patients with severe disorders of consciousness was achieved following irradiation at 785 nm, a somewhat uncommon wavelength for transcranial PBM therapy

4.4. Stroke

To date, three clinical trials, called “Neurothera Effectiveness and Safety Trials” (NEST-1 [199], NEST-2 [90], and NEST-3 [200]) have been carried out in acute stroke patients. Although the phase I and II studies showed both the safety and effectiveness of PBM therapy using 808 nm laser (applied within 24 h of stroke onset), phase III trials were disappointing and were terminated for futility at an interim analysis stage. Besides these, an effort has been made in occasional studies to show neuroprotective or neuroreparative effects of PBM therapy in chronic stroke patients via transcranial [181] and multiple area [201] irradiation methods.

 

5.5. Depression

The development of effective and sustainable treatment modalities for major depression has been a global aim for decades. To date, studies on antidepressant effects of PBM therapy have had relatively short follow-up periods and could be divided into two types of studies, patients with MDD [11,202,203] and TBI patients with comorbid depression [30,33,61]. The first study in MDD patients showed that a single-session of LED therapy alleviated depression and anxiety symptoms

Ischemic Stroke Treat Multi Frequency Photobiomodulation Helmet 3

 

Ischemic Stroke Treat Multi Frequency Photobiomodulation Helmet 4Ischemic Stroke Treat Multi Frequency Photobiomodulation Helmet 5Ischemic Stroke Treat Multi Frequency Photobiomodulation Helmet 6

Compared with other therapy method, like drugs, light therapy is the most safe and no side effects way for treatment.


Light therapy was known in medical field for a long time, especially for the red light and infrared.
All our clients feel good spirit and comfortable after using.


Our device works with 810nm infrared, it can extend through the skull into the brain, offers an unique array of neurological benefits. It usually be used for treating metastatic lesions in deep tissues as well as in bones. And also be used for cancer cell imaging, as well as circulating tumor cell detection and destruction.

 

1.The 810 nm wavelength has the ability to extend through the skull to the brain, promoting recovery from traumatic brain injury and reducing long-term nerve damage.
2.810nm wavelength can help patients with severe depression and anxiety
3. NIR light is absorbed by cytochrome C oxidase in mitochondria.
4. Increased blood flow, energy, neuroprotection and less inflammation.
5. treat traumatic (stroke, TBI), neurodegenerative and psychiatric diseases.

 

Abstract:

A new piece of equipment for LED (light emitting diode) brain photobiomodulation is introduced. Preliminary results from regional cerebral oxygen saturation and from thermography are shown before, during and after stimulation.

 

The procedure offers a new way to quantify the biological effects of a possible innovative therapeutic method. However further measurements are absolutely necessary.

 

The Brain Photobiomodulation Machine is a therapeutic instrument based on the principle of photobiomodulation. It has a good therapeutic effect on traumatic events (stroke, traumatic brain injury, and global ischemia), degenerative diseases (dementia, Alzheimer’s and Parkinson’s), and psychiatric disorders (depression, anxiety, post traumatic stress disorder)

 

Brain photobiomodulation (PBM) with red to near-infrared (NIR) light emitting diodes (LED) could be an innovative therapy for a variety of neurological and psychological disorders. Red/NIR light can stimulate mitochondrial respiratory chain complex IV (cytochrome c oxidase) and increase ATP (adenosintriphosphate) synthesis. In addition, light absorption by ion channels leads to the release of Ca2+ and to the activation of transcription factors and gene expression. Brain PBM therapy could improve the metabolic capacity of neurons and is able to stimulate anti-inflflammatory, anti-apoptotic and antioxidant responses as well as neurogenesis and synaptogenesis. Findings suggest that PBM may enhance, for example, the frontal brain functions of older adults in a safe and cost-effective manner.

Ischemic Stroke Treat Multi Frequency Photobiomodulation Helmet 7

Note the increase in the regional cerebral oxygen saturation during and after stimulation on the left and right side.

Ischemic Stroke Treat Multi Frequency Photobiomodulation Helmet 8

Results from thermal imaging of the first pilot measurement using the new stimulation helmet. Note the increase in temperature on the helmet (upper row; a before, b during, and c after stimulation) on the forehead (middle row; d–f) and on the chin (lower row; g–i).

 

Main Function

1.The 810 nm wavelength has the ability to extend through the skull to the brain, promoting recovery from traumatic brain injury and reducing long-term nerve damage.

2.810nm wavelength can help patients with severe depression and anxiety

3.NIR light is absorbed by cytochrome C oxidase in mitochondria.

4.Increased blood flow, energy, neuroprotection and less inflammation.

5.treat traumatic (stroke, TBI), neurodegenerative and psychiatric diseases.

 

Indications

  1. Traumatic events (stroke, traumatic brain injury, and global ischemia).
  2. Degenerative diseases (dementia, Alzheimer’s and Parkinson’s).
  3. Psychiatric disorders (depression, anxiety, post traumatic stress disorder).

 

Contraindication

  1. Avoid direct exposure to the eyes, pregnant woman’sabdomen, melanoma, brown spots.
  2. Taboo patients with early and middle stage malignant tumors.
  3. Contraindications to patients with acute bleeding disorders.

 

PBM therapy was developed more than 50 years ago; however, there is still no common agreement on the parameters and protocols for its clinical application. Some research teams have recommended the use of a power density of less than 100 mW/cm2 and an energy density of 4 to 10 J/cm2. Others groups recommend as much as 50 J/cm2 at the tissue surface. Parameters like wavelength, energy, flfluence, power, irradiance, pulse mode, treatment duration, and repetition rate can be applied in a wide range. Our present preliminary results showed a clear response of cerebral rSO2 in relation to the LED stimulation. However, it has to be mentioned that the temperature increased signifificantly, and these effects have to be taken into account in further studies in detail. There is also the fact that ineffective studies in cells with high mitochondrial activity appear to be due more often to over-dosing than to under-dosing. Therefore, clinical studies concerning the optimal stimulation doses are necessary.

Transcranial PBM appears promising to treat different mental diseases. Pitzschke et al. also measured light propagation in different areas of Parkinson’s disease (PD)-relevant deep brain tissue during transcranial and transsphenoidal illumination (at 671 and 808 nm) of a cadaver head and modeled optical parameters of human brain tissue using Monte-Carlo simulations. This study demonstrates that it is possible to also illuminate deep brain tissues transcranially and transsphenoidally. This opens therapeutic options for sufferers of PD or other cerebral diseases necessitating light therapy. There have been several investigations concerning possible adverse effects for LED PBM.

For example, Moro et al. explored the effects of longer term application, up to 12 weeks, of PBM (670 nm) in normal, naïve macaque monkeys. They found no histological basis for any major biosafety concerns associated with PBM delivered by an intracranial approach. Hennessy and Hamblin also pointed out the already established safety and notable lack of adverse effects of transcranial PBM. The preliminary results are very promising; however, further research work is required in order to be able to use, for example, this new kind of PBM as a therapeutic method. Many investigatorsbelieve that PBM with LED and/or laser for brain disorders will become one of the most important medical applications of light therapy in the coming years and decades.

Reference: Brain Photobiomodulation – Preliminary Results from Regional Cerebral Oximetry and Thermal Imaging

Ischemic Stroke Treat Multi Frequency Photobiomodulation Helmet 9

Ischemic Stroke Treat Multi Frequency Photobiomodulation Helmet 10

Ischemic Stroke Treat Multi Frequency Photobiomodulation Helmet 11

Specifications

Name Brain Photobiomodulation Machine
Model GY-PDT1
LED Wavelength 810 nm
Led Quantity 256pcs
Power(total helmet) 15 W
Power(one LED) 60 mW
Power 24 mW/cm2
Certificate CE, FDA
OEM Support
Color White/Black
Option Time

6-12-18-24-30 minutes

 

 

Ischemic Stroke Treat Multi Frequency Photobiomodulation Helmet 12

 

Reference: Brain Photobiomodulation – Preliminary Results from Regional Cerebral Oximetry and Thermal Imaging

Please read the following notes carefully beforehand
Please follow the manufacturer to develop a special transformer and power outlet to ensure the normal operation of the product.
Do not place the product in direct sunlight or near flammable materials.
Do not disassemble it yourself to avoid electric shock.
Do not scrub with an acidic or alkaline cleaner.
Do not use the product in a place with high temperature or high humidity.
Disconnect the power and unplug the power adapter when you are not using the product or when you are absent.
Do not use the power cord for knotting, bundling, etc., and do not use when the outer skin is damaged.
Do not use the multi-function adapter socket.
Make sure the power outlet meets manufacturers specifications
In the following situations, please unplug the power cord and stop using it.
* When the product and power adapter are wet or drenched.
* Safety factors such as smoke and sparks occur on the line.
*When the power cord or power plug is damaged or broken.
(If you have any questions, please contact the after-sales customer service staff

This product is guaranteed for one year free service under normal use. If the warranty period is exceeded, a certain part cost will be charged.

mitochondiral.jpg

Research indicates that cytochrome c oxidase(CCO, also known as complex IV) is a key photo-acceptor of irradiation in the red to near infrared range, responsible for the final reduction of oxygen to water using the electrons generated from glucose metabolism.

There are several mechanisms associated with promoting physiological change through photobiomodulation therapy (PBMT). The wavelengths primarily used with PBM is within the near-infrared range of the electromagnetic spectrum with a sufficient power density. When hypoxic/impaired cells are irradiated with low level NIR photons, there is increased mitochondrial adenosine tri-phosphate (ATP) production within their mitochondria.

Another change is the release of nitric oxide(NO) from the hypoxic/impaired cells. Neurons are cells that contain mitochondria and nitric oxide.

In hypoxic neuronal cells, cytochrome-C oxidase (CCO), a membrane-bound protein that serves as the end-point electron acceptor in the cell respiration electron transport chain, becomes inhibited by non-covalent binding of nitric oxide. When exposed to NIR photons, the CCO releases nitric oxide, which then diffuses outs of the cell – increasing local blood flow and vasodilation.

Following initial exposure to the NIR photons, there is a brief burst of reactive oxygen species (ROS) in the neuron cell, and this activates a number of signaling pathways. The ROS leads to activation of redox-sensitive genes, and related transcription factors including NF-κβ.5, 6 The PBMT stimulates gene expression for cellular proliferation, migration, and the production of anti-inflammatory cytokines and growth factors.

This product is guaranteed for one year free service under normal use. If the warranty period is exceeded, a certain part cost will be charged.

No claims are made or implied other than registered intended use for topical heating. Information is for research purposes only.

ssch-pbm-helmet-introduction.jpg

References for Research

PBM for Stroke

https://www.ncbi.nlm.nih.gov/pubmed/30983970

https://www.ncbi.nlm.nih.gov/pubmed/29472564

https://www.ncbi.nlm.nih.gov/pubmed/22967677

PBM for Traumatic Brain Injury

https://www.ncbi.nlm.nih.gov/pubmed/28001756

https://www.ncbi.nlm.nih.gov/pubmed/26990361

https://www.ncbi.nlm.nih.gov/pubmed/25966949

PBM for Alzheimers

https://www.ncbi.nlm.nih.gov/pubmed/27815990

https://www.ncbi.nlm.nih.gov/pubmed/28186867

https://www.ncbi.nlm.nih.gov/pubmed/31050950

PMB for Parkinsons

https://www.ncbi.nlm.nih.gov/pubmed/25462595

https://www.ncbi.nlm.nih.gov/pubmed/19534794

https://www.ncbi.nlm.nih.gov/pubmed/26484876

PMB for Psychiatric Disorders

https://www.ncbi.nlm.nih.gov/pubmed/22334326

https://www.ncbi.nlm.nih.gov/pubmed/19995444

https://www.ncbi.nlm.nih.gov/pubmed/29307593

You Might Be Into These
Get in touch with us

Enter Your Message

sale05@sschgroup.com
michael810815
llmm928@yahoo.com.cn